Compare

Arrowhead Pharmaceuticals, Inc. vs Zai Lab Ltd vs Nature's Sunshine Products Inc vs Travere Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearArrowhead Pharmaceuticals, Inc.
ARWR
Zai Lab Ltd
ZLAB
Nature's Sunshine Products Inc
NATR
Travere Therapeutics, Inc.
TVTX
Year ended2026-09-302025-12-312025-12-312025-12-31
Revenue$450.82M$457.18M$480.14M$490.73M
Revenue growth (YoY)-45.6%+15.0%+5.7%+110.5%
Gross marginn/a58.3% (computed)72.4%n/a
Operating margin-156.9%-50.2%5.2%-12.8%
Net margin-159.1%-38.4%4.3%-5.2%
Net income-$717.13M-$175.54M$20.45M-$25.55M
EPS (Diluted)-$5.11-$0.16$1.06-$0.29
Operating cash flow-$271.95M-$150.79M$35.32M$37.78M
Free cash flow-$283.94M-$158.89M$28.84Mn/a
Cash & equivalentsn/a$679.57M$93.89M$93.03M
Total assets$1.74B$1.17B$261.15M$605.19M
Total liabilitiesn/a$456.88M$99.59M$490.36M
Shareholders' equity$50.50M$715.50M$161.55M$114.83M
Return on year-end equityn/m-24.5%12.7%-22.2%
Shares outstanding141.29M1.11B17.51M90.92M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearArrowhead Pharmaceuticals, Inc.Zai Lab LtdNature's Sunshine Products IncTravere Therapeutics, Inc.
Latest$450.82M
Ended 2026-09-30
$457.18M
Ended 2025-12-31
$480.14M
Ended 2025-12-31
$490.73M
Ended 2025-12-31
1 year earlier$829.45M
Ended 2025-09-30
$397.61M
Ended 2024-12-31
$454.36M
Ended 2024-12-31
$233.18M
Ended 2024-12-31
2 years earlier$3.55M
Ended 2024-09-30
$266.72M
Ended 2023-12-31
$445.32M
Ended 2023-12-31
$145.24M
Ended 2023-12-31
3 years earlier$240.74M
Ended 2023-09-30
$212.67M
Ended 2022-12-31
$421.91M
Ended 2022-12-31
$109.46M
Ended 2022-12-31
4 years earlier$243.23M
Ended 2022-09-30
$144.10M
Ended 2021-12-31
$444.08M
Ended 2021-12-31
$131.84M
Ended 2021-12-31